Q:What are your views on the development hotspots of China's big health industry in the coming years?
Wang Xin:In recent years, China's healthcare industry has maintained overall stability and rapid growth. Driven by factors such as economic growth, policy support, technological progress, and capital assistance, the healthcare industry has gradually become a strategic pillar industry of China's national economy, entering a golden development period.
The global healthcare system is also accelerating its transformation into a digital healthcare system, entering a new normal of global digital healthcare. Under this influence, China's healthcare industry and its sub-sectors, such as pharmaceuticals, medical devices, and digital medicine, have entered a critical stage of industrial chain upgrading, transformation, integration, and reorganization. These areas will become several hotspots in investment over the next decade.
Q:What is the development trend of the in vitro diagnostic (IVD) industry in the coming years? Is it promising that health insurance and healthcare management will integrate their future development, and what trends are expected?
Wang Xin:Health insurance and in vitro diagnostic (IVD) are two important sub-sectors within the broader healthcare sector, facing rapid growth opportunities. At the same time, the improvement of policies and regulations in our country has also led the health insurance and IVD industries to develop in a more standardized direction.
The in vitro diagnostic (IVD) industry is an important segment within the broader healthcare sector. It has developed rapidly in recent years, especially after the outbreak of the COVID-19 pandemic last year, becoming one of the hottest areas in the medical device industry. The entire upstream and downstream industrial chain is also gradually maturing during development.
In the future, the degree of localization in China's in vitro diagnostic industry will gradually increase. Domestic enterprises will gradually break the monopoly previously held by foreign companies, with domestic brands gradually replacing imported ones. The technological gap will further narrow, and their comprehensive competitiveness will significantly improve. In addition, the market share of immunodiagnostic products has gradually surpassed that of biochemical diagnostic products, and it is expected to become the largest in vitro diagnostic subcategory in terms of domestic market size.
In addition, we are very optimistic about the future space for the integrated development of health insurance and health management. According to Frost & Sullivan's observations and research, there are three major trends in integrated development: First, the combination of health insurance with healthcare, integrating medical resources such as physical examinations, screenings, and rehabilitation to create a closed-loop health management system throughout the life cycle; second, adopting a mixed development model that combines public and private sectors to promote the upgrading of the health management service industry; third, implementing product differentiation strategies based on different customers and needs to help health management enterprises gain more market opportunities.
askFor healthcare companies, what are the main indicators for measuring growth?
Wang Xin:"Growth" should not be solely limited to numerical metrics such as business scale or revenue growth rate. It is more about whether enterprises can continuously seek breakthroughs and innovations in their respective fields and tracks, and whether they can create value for industrial development, people's livelihoods, and economic growth.
Taking the healthcare sector as an example, we believe that indicators of growth should be reflected in technological transformation, model innovation, product iteration, application expansion, and other aspects.
*This article is reprinted from Xinhua Finance and Economics, authored by Shen Yinfei. Click at the bottomRead the original textYou can view the original news report by clicking
